Edoxaban T300 26-27

Edoxaban

Savaysa

Edoxaban Drug Class

Factor Xa Inhibitor

Edoxaban Dosage Forms

Oral Tablet: 15 mg, 30 mg, 60 mg

Edoxaban Dosing By Indication

1. Nonvalvular atrial fibrillation (prophylaxis, to reduce the risk of stroke): Adults, weight >60 kg, 60 mg po once daily, weight ≤60 kg, 30 mg po once daily

2. Venous thromboembolism (treatment, following 5-10 d of parenteral anticoagulant): Adults, weight >60 kg, 60 mg po once daily, weight ≤60 kg, 30 mg po once daily

Edoxaban Off Label Uses

1. Prophylaxis of thrombosis post arthroplasty of knee: 30 mg po daily, beginning 6-24 h postoperatively and continuing for 11-14 d

Edoxaban MOA

This drug is a selective inhibitor of FXa. By inhibiting FXa, it decreases thrombin generation and thrombus development.

Edoxaban Common Adverse Effects

Bleeding

Edoxaban Efficacy Monitoring Parameters

Absence of thrombosis if used for prophylaxis. Resolution of DVT or PE if used for treatment. If concern for supratherapeutic edoxaban concentrations, obtain an anti-factor Xa level specific to edoxaban.

Edoxaban Safety Monitoring Parameters

Baseline LFTs, SCr, aPTT, PT, CBC, repeat yearly and as indicated. Assess for signs of bleeding.

Edoxaban Key Counseling Points

Seek medical attention if any unexpected bleeding or trouble breathing. Take with or without food. Do not stop taking edoxaban without talking with your HCP; stopping early may increase the risk of stroke, especially in patients with atrial fibrillation. Edoxaban may be discontinued 24-48 h prior to dental and surgical procedures and restarted after hemostasis, following consultation with a HCP. Avoid OTC NSAIDs and high-dose aspirin, as they increase the risk of bleeding. If difficulty swallowing tablets, may crush and mix in water or applesauce for administration.

Edoxaban Clinical Pearls

Avoid concurrent use with heparin or warfarin. When converting from warfarin to edoxaban, discontinue warfarin once INR <2.5, and give the first edoxaban dose at the time the next scheduled dose of warfarin was to have been given. If converting from a parenteral anticoagulant to edoxaban, dose edoxaban at the next scheduled time of the discontinued anticoagulant. In the event of a major bleed, may consider administration of prothrombin complex concentrates as currently no reversal agent is approved for edoxaban.